North America CNS Drugs Market Size, Share, Growth and Forecast, 2025-2035

North American CNS drug sales grow on new mechanisms

The North America CNS drugs market was valued at USD 73.80 billion in 2025 and is projected to increase from USD 77.75 billion in 2026 to USD 124.80 billion by 2035, registering a CAGR of 5.39% during 2025–2035. Demand comes from first-in-class psychiatric drugs, high-priced antibody and gene therapies for rare nerve and muscle diseases, an older population with more Parkinson’s disease and dementia, and wider diagnosis of depression, anxiety and ADHD. The United States held the largest country share, 92.0% in 2025, because it launches new brands first and pays the highest prices. Mexico, by contrast, is the fastest-growing country at 6.59% a year. The main commercial change is the shift from daily pills toward long-acting injections and home self-injection of biologics, while patent expiries and Medicare price negotiation squeeze older multiple sclerosis, epilepsy and ADHD brands.

Which prescription medicines count toward North American CNS drug sales?

The estimate counts branded and generic prescription drugs for disorders of the brain, spinal cord and nerves across 3 countries. Psychiatric drugs cover schizophrenia, bipolar disorder, depression, anxiety, ADHD and sleep disorders. Neurology drugs cover multiple sclerosis, migraine, epilepsy, movement disorders, neuromuscular disorders and Alzheimer’s disease. All dosage forms are included, valued after rebates and discounts.

Pain medicines, opioids, anesthetics and drugs for brain cancers are excluded, as are over-the-counter sleep aids, supplements and devices such as neurostimulators. Medicare, Medicaid, private insurers and provincial or public plans pay most of the bill.

Multiple sclerosis and pills lead as Alzheimer’s drugs gain

Multiple sclerosis leads while Alzheimer’s drugs grow fastest

Based on therapeutic area, the market is categorized into multiple sclerosis, schizophrenia and bipolar disorder, movement disorders, neuromuscular disorders, migraine, ADHD and sleep disorders, depression and anxiety, epilepsy and Alzheimer’s disease and dementia. Multiple sclerosis led with a 19.4% share of 2025 value, because antibodies such as Ocrevus and Kesimpta are used for years. Alzheimer’s disease and dementia grows fastest at 21.40% a year from a small base as anti-amyloid antibodies reach more patients.

Pills keep volume while injectables add growth

Based on route of administration, the market is categorized into oral, injectable and infusion, and nasal, transdermal and other forms. Oral drugs led with a 54.0% share of 2025 value, because most antipsychotics, antidepressants, stimulants and anticonvulsants are taken as pills, many of them generic. Injectable and infused drugs grow fastest at 6.94% a year, lifted by long-acting antipsychotic injections, neurology antibodies and the move from hospital infusion to self-injection at home.

New mechanisms and rare-disease biologics drive demand

First new schizophrenia mechanism in decades opens fresh prescribing

For decades, schizophrenia drugs worked by blocking dopamine, but in September 2024, the U.S. Food and Drug Administration approved Cobenfy, the first schizophrenia drug with a new mechanism of action in decades. In November 2025, Johnson & Johnson announced FDA approval of Caplyta as an add-on treatment for major depressive disorder, according to Johnson & Johnson. Psychiatrists treating patients who fail 2 or more older drugs gain options, which drives demand for the new brands, and the effect builds over the medium term as Medicaid and Medicare plans list the brands.

Antibodies and gene therapies turn rare nerve diseases into high-value classes

Antibody and fusion-protein drugs now treat myasthenia gravis, neuromyelitis optica and other rare nerve and muscle diseases, and gene and RNA therapies treat spinal muscular atrophy. These medicines carry high prices and are used for years, so a few thousand patients add large value, mostly in U.S. specialist centers, where argenx leads in myasthenia gravis. The effect is long term, because each approval in a new rare disease adds a decade of revenue.

Download Free Sample

An older population raises Parkinson’s, dementia and movement disorder treatment

Parkinson’s disease, tardive dyskinesia and dementia rise sharply with age across the United States and Canada. In July 2024, the FDA approved Eli Lilly’s Kisunla for early Alzheimer’s disease, giving doctors a second anti-amyloid antibody after Leqembi. Each treated patient needs regular infusions or injections and brain scans, so value per patient is high. As a result, Alzheimer’s disease and dementia drugs grow at 21.40% a year, and the effect strengthens after 2030 as more patients qualify.

Wider diagnosis and protected drug classes sustain psychiatric prescriptions

More adults are diagnosed with ADHD, depression and anxiety, and telehealth makes starting treatment easier. At the same time, Medicare Part D protected-class rules limit how far plans restrict antipsychotics, antidepressants and anticonvulsants. Centers for Medicare & Medicaid Services data show U.S. retail prescription drug spending rose 7.9% to USD 467.0 billion in 2024, after 10.8% in 2023. However, much new volume uses low-cost generics, so prescriptions grow faster than value through 2035.

Long-acting injections and home dosing change CNS care

Long-acting antipsychotic injections gain ground in schizophrenia

Monthly, 2-monthly and 6-monthly antipsychotic injections reduce missed doses and relapse, and their use is rising across community mental health services. The shift supports value even as oral antipsychotics turn generic, because a single injection carries a branded price. Johnson & Johnson’s Invega range and the Abilify injectables from Otsuka and Lundbeck lead the format, though uptake is faster in integrated health systems than in solo practices with limited clinic capacity.

Neurology biologics shift from infusion chairs to home autoinjectors

Drug makers are moving neurology antibodies from hospital infusion to injections at home. In August 2025, Eisai and Biogen announced FDA approval of Leqembi Iqlik, a subcutaneous autoinjector for maintenance treatment of early Alzheimer’s disease, according to Biogen. Injectable and infused drugs grow at 6.94% a year, the fastest route, because home dosing frees infusion capacity, lowers site-of-care cost for payers and favors specialty pharmacies, rewarding brands with simple devices.

Download Free Sample

Preventive migraine care opens an opportunity

CGRP-blocking pills and antibodies have moved migraine care from rescue to prevention, and Pfizer, Eli Lilly and AbbVie all compete in the class. Many patients with 4 or more headache days a month still use only acute drugs, which leaves room for neurologists and primary care doctors to add preventive therapy. Companies that win formulary placement with large U.S. pharmacy benefit managers and secure step-therapy exceptions can expand use well before 2035.

Late-stage CNS assets offer an acquisition opportunity

Large drug makers refill pipelines by buying CNS specialists, and in March 2024, Bristol Myers Squibb acquired Karuna Therapeutics and with it Cobenfy. In April 2025, Johnson & Johnson acquired Intra-Cellular Therapies, the maker of Caplyta. Biotechs with Phase 3 psychiatric or rare-neurology assets, such as Axsome Therapeutics, stand to gain. Buyers favor 1 or 2 differentiated mechanisms with clear U.S. launch paths over broad early pipelines, which supports biotech valuations.

Generic entry and Medicare negotiation hold back revenue

Patent expiries erode multiple sclerosis, epilepsy and ADHD brands

Several large multiple sclerosis, epilepsy and ADHD drugs have already turned generic, and more brands lose exclusivity before 2035. Generic and biosimilar entry cuts net prices sharply within 1 to 2 years, which hits the companies that rely on a single franchise and slows growth in multiple sclerosis, the largest therapeutic area at 19.4% of 2025 value. Makers respond with long-acting or subcutaneous versions, new indications and earlier launches of follow-on products, but each step needs its own trial and payer review.

Payer controls and Medicare price negotiation squeeze branded neurology drugs

Insurers use prior authorization and step therapy for expensive brands, especially in migraine, ADHD and multiple sclerosis. Medicare drug price negotiation adds pressure on older, high-spend products used by people aged 65 and over, which slows uptake and lowers net prices for second- and third-line brands. Companies mitigate the risk with outcome data, patient support programs and lifecycle plans that move volume to newer, protected products before negotiation dates.

High placebo response and late-stage failures raise CNS development risk

Brain disorders are hard to measure, and placebo responses are high in psychiatric trials, so many Phase 3 CNS programs fail. Each failure wastes years of spending and thins the flow of new products that would replace expiring brands. Small biotechs face the greatest funding risk, and developers reduce it with biomarkers, enriched trial populations and partnerships with large companies that can fund 2 or more confirmatory studies and absorb a setback.

Brain scans and supervised dosing slow uptake of newer CNS drugs

Some newer drugs need special monitoring, such as MRI brain scans for anti-amyloid antibodies or supervised dosing for nasal esketamine. These rules add clinic time and cost, so uptake concentrates in large treatment centers and lags in rural areas of all 3 countries, and revenue per launch builds more slowly. Subcutaneous dosing, simpler monitoring schedules and wider imaging capacity are the main ways makers and health systems reduce the friction.

The United States dominates while Mexico grows fastest

United States leads with first launches and the highest prices

The United States held a 92.0% share of 2025 value and grows at 5.39% a year. It launches new CNS drugs first, pays the highest prices and has the largest neurology and psychiatry specialist networks. Retail drug prices rose only 1.4% in 2024, according to CMS, so utilization and new brands drove most of the 7.9% spending gain. Medicare price negotiation is the main factor that could slow branded CNS revenue.

Canada's provincial formularies pace the uptake of new neurology biologics

Canada held a 6.0% share of 2025 value and grows at 4.99% a year. Health Canada approvals usually follow the FDA, and provincial drug plans negotiate prices through a national alliance before listing new brands, which slows the uptake of costly neurology biologics and anti-amyloid antibodies compared with U.S. commercial plans. Generic substitution in psychiatry and epilepsy is high, so new value comes mainly from multiple sclerosis, migraine prevention and rare neuromuscular diseases.

Download Free Sample

Mexico's private hospitals and insurers make it the fastest-growing country

Mexico held 2.0% of 2025 value and is the fastest-growing country at 6.59% a year. Public institutions rely mainly on generics for epilepsy, depression and schizophrenia, while private hospitals and insurers in large cities drive demand for newer branded drugs as private coverage and specialist care expand. Branded launches usually reach Mexico 1 or more years after U.S. approval, which keeps its share small despite faster growth.

Download Free Sample

Psychiatry approvals and 2 takeovers mark 2024–2025

Muscarinic drugs, subcutaneous antibodies and gene therapy

• Mechanisms in muscarinic antipsychotics such as Cobenfy break the 70-year reliance on dopamine blockade and open a new class for patients who fail older drugs.
• Delivery through long-acting injections given every 1, 2 or 6 months and subcutaneous autoinjectors for antibodies moves treatment out of clinics and improves adherence.
• Biologics such as antibodies, fusion proteins and gene and RNA therapies extend treatment to rare nerve and muscle diseases with high prices and long use.
• Regulation through Medicare price negotiation, protected-class rules and safety monitoring requirements shapes launch pricing, uptake speed and lifecycle plans for every brand.

CNS majors defend brands as rare-disease biotechs rise

The field splits into 3 groups, led by neuroscience majors that hold the largest brands. AbbVie leads in psychiatry with Vraylar, Johnson & Johnson holds Invega long-acting injectables, Spravato and Caplyta, and Roche and Novartis lead multiple sclerosis with Ocrevus and Kesimpta. Specialist CNS companies such as Neurocrine Biosciences, Teva, Otsuka, Lundbeck, Axsome Therapeutics and Alkermes focus on a few disorders, including movement disorders, depression and sleep. Rare-disease and biologics companies, led by argenx in myasthenia gravis and Biogen and Eisai with Leqembi, compete on new mechanisms. No company reports North American CNS sales on a comparable basis, so no share ranking is given.

Companies profiled and their roles

CNS value moves from mature pills to new biologics

Credence Research’s view is that North American CNS drug value is shifting from large, maturing pill franchises, which make oral drugs 54.0% of 2025 value, to first-in-class drugs and biologics with narrower but better-paying patient groups. The largest new revenue lies in neuromuscular biologics, new-mechanism psychiatric drugs and Alzheimer’s antibodies, and companies that pair a differentiated mechanism with convenient dosing are best placed. The main risk is net price erosion from Medicare negotiation and generic entry, so investors should watch Phase 3 readouts, subcutaneous launches, Mexican private insurance growth and CMS negotiation lists.

Filings, generic volumes and CMS data underpin the estimate

The report uses 2025 as the base year and forecasts to 2035. Values come from Credence Research’s model, built from branded CNS product sales in company filings and from prescription volumes and net prices for generic classes, checked against national prescription drug spending; therapeutic area, route and country splits are Credence Research estimates. Supporting evidence comes from company filings, FDA approval notices and CMS spending data.

Value tilts from blockbuster pills to specialist biologics

Through 2035, CNS drug value in North America will tilt from blockbuster pills toward specialist biologics, long-acting injections and first-in-class psychiatric drugs. Alzheimer’s antibodies will grow fastest as subcutaneous dosing widens access, while multiple sclerosis and epilepsy slow as generics spread. The pace will depend on Medicare negotiation outcomes, Phase 3 success rates and how quickly provincial and private plans list new drugs, which together carry the market from USD 77.75 billion in 2026 to USD 124.80 billion by 2035.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.